Literature DB >> 21894442

IL-17 receptor and its functional significance in psoriatic arthritis.

Siba P Raychaudhuri1, Smriti K Raychaudhuri, Mark C Genovese.   

Abstract

To delineate the functional significance of IL-17 Receptor (IL-17RA) and characterize the IL-17 producing T cell (Th17) subpopulation in psoriatic arthritis (PsA). Mononuclear cells from blood and synovial fluid (SF) were obtained from PsA (n=20), rheumatoid arthritis (RA, n=20) and osteoarthritis (OA, n=20) patients. Synoviocytes (FLS) were isolated from the synovium of RA (n=5), PsA (n=5) and OA (n=5) patients. IL-17RA expression in FLS was identified by western blotting (WB) and flowcytometry. T lymphocytes derived from the SF of these patients were studied to identify and phenotype the Th17 cells. The functional significance of IL-17RA was determined by evaluating its regulatory role on the production of proinflammatory cytokines and endopeptidase. IL-17RA expression was found to be significantly higher in FLS of RA (15.7%±4.9) and PsA (4.5%±0.9) in comparison to OA (1.14%±0.9). Western blot analyses showed that the relative intensity (RI) of IL-17RA protein was higher in RA and PsA compared to OA (Fisher exact, P<0.01). A significant enrichment of IL-17-producing CD4+ T cells (7.9%±2.8) was observed in the SF of PsA patients compared to that of OA patients (P<.001). Compared to OA-FLS, recombinant IL-17 induced higher levels of IL-6, IL-8, and MMP-3 production in PsA-FLS. Blockage of IL-17RA with an anti-IL-17RA antibody inhibited the production of IL-6, IL-8, and MMP-3. This is the first report to demonstrate the functional significance of IL-17RA in PsA. Results of this study support the hypothesis that IL-17RA blocking antibodies have the potential to be a therapeutic option for psoriatic arthritis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21894442     DOI: 10.1007/s11010-011-1036-6

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  50 in total

1.  Psoriatic arthritis.

Authors:  V Wright; J M Moll
Journal:  Bull Rheum Dis       Date:  1971-01

2.  High in vivo expression of interleukin-17 receptor in synovial endothelial cells and chondrocytes from arthritis patients.

Authors:  M C Honorati; R Meliconi; L Pulsatelli; S Canè; L Frizziero; A Facchini
Journal:  Rheumatology (Oxford)       Date:  2001-05       Impact factor: 7.580

3.  In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin.

Authors:  Gamze Piskin; Regien M R Sylva-Steenland; Jan D Bos; Marcel B M Teunissen
Journal:  J Immunol       Date:  2006-02-01       Impact factor: 5.422

4.  Expression, modulation and signalling of IL-17 receptor in fibroblast-like synoviocytes of patients with rheumatoid arthritis.

Authors:  A Kehlen; K Thiele; D Riemann; J Langner
Journal:  Clin Exp Immunol       Date:  2002-03       Impact factor: 4.330

5.  IL-17 is produced by nickel-specific T lymphocytes and regulates ICAM-1 expression and chemokine production in human keratinocytes: synergistic or antagonist effects with IFN-gamma and TNF-alpha.

Authors:  C Albanesi; A Cavani; G Girolomoni
Journal:  J Immunol       Date:  1999-01-01       Impact factor: 5.422

6.  Interleukin 17 induces cartilage collagen breakdown: novel synergistic effects in combination with proinflammatory cytokines.

Authors:  P J Koshy; N Henderson; C Logan; P F Life; T E Cawston; A D Rowan
Journal:  Ann Rheum Dis       Date:  2002-08       Impact factor: 19.103

7.  Psoriasis, psoriatic arthritis, or psoriatic disease?

Authors:  Raffaele Scarpa; Fabio Ayala; Nicola Caporaso; Ignazio Olivieri
Journal:  J Rheumatol       Date:  2006-02       Impact factor: 4.666

8.  Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis.

Authors:  Christopher T Ritchlin; Sally A Haas-Smith; Ping Li; David G Hicks; Edward M Schwarz
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

9.  Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense.

Authors:  P Ye; F H Rodriguez; S Kanaly; K L Stocking; J Schurr; P Schwarzenberger; P Oliver; W Huang; P Zhang; J Zhang; J E Shellito; G J Bagby; S Nelson; K Charrier; J J Peschon; J K Kolls
Journal:  J Exp Med       Date:  2001-08-20       Impact factor: 14.307

10.  IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis.

Authors:  Jason R Chan; Wendy Blumenschein; Erin Murphy; Caroline Diveu; Maria Wiekowski; Susan Abbondanzo; Linda Lucian; Richard Geissler; Scott Brodie; Alexa B Kimball; Daniel M Gorman; Kathleen Smith; Rene de Waal Malefyt; Robert A Kastelein; Terrill K McClanahan; Edward P Bowman
Journal:  J Exp Med       Date:  2006-10-30       Impact factor: 14.307

View more
  71 in total

Review 1.  Secukinumab: a promising therapeutic option in spondyloarthritis.

Authors:  Hernan Maldonado-Ficco; Rodolfo Perez-Alamino; José A Maldonado-Cocco
Journal:  Clin Rheumatol       Date:  2016-07-20       Impact factor: 2.980

2.  Cross talk between neuroregulatory molecule and monocyte: nerve growth factor activates the inflammasome.

Authors:  Ananya Datta-Mitra; Smriti Kundu-Raychaudhuri; Anupam Mitra; Siba P Raychaudhuri
Journal:  PLoS One       Date:  2015-04-15       Impact factor: 3.240

Review 3.  Role of IL-17 in the pathogenesis of psoriatic arthritis and axial spondyloarthritis.

Authors:  Smriti K Raychaudhuri; Ankit Saxena; Siba P Raychaudhuri
Journal:  Clin Rheumatol       Date:  2015-05-05       Impact factor: 2.980

Review 4.  Targeting IL-17 in psoriatic arthritis.

Authors:  Elizabeth A Wang; Erika Suzuki; Emanual Maverakis; Iannis E Adamopoulos
Journal:  Eur J Rheumatol       Date:  2017-11-10

Review 5.  The Bench-to-Bedside Story of IL-17 and the Therapeutic Efficacy of its Targeting in Spondyloarthritis.

Authors:  Judith A Smith
Journal:  Curr Rheumatol Rep       Date:  2016-06       Impact factor: 4.592

6.  Psoriatic inflammation facilitates the onset of arthritis in a mouse model.

Authors:  Mayuko Yamamoto; Kimiko Nakajima; Mikiro Takaishi; Shun Kitaba; Yasuhiro Magata; Sayo Kataoka; Shigetoshi Sano
Journal:  J Invest Dermatol       Date:  2014-09-30       Impact factor: 8.551

Review 7.  Inflammatory Joint Disorders and Neutrophilic Dermatoses: a Comprehensive Review.

Authors:  Massimo Cugno; Roberta Gualtierotti; Pier Luigi Meroni; Angelo Valerio Marzano
Journal:  Clin Rev Allergy Immunol       Date:  2018-04       Impact factor: 8.667

Review 8.  Role of IL-17 in psoriasis and psoriatic arthritis.

Authors:  Siba P Raychaudhuri
Journal:  Clin Rev Allergy Immunol       Date:  2013-04       Impact factor: 8.667

9.  IL-17A receptor expression differs between subclasses of Langerhans cell histiocytosis, which might settle the IL-17A controversy.

Authors:  Ichiro Murakami; Akira Morimoto; Takashi Oka; Satoshi Kuwamoto; Masako Kato; Yasushi Horie; Kazuhiko Hayashi; Jean Gogusev; Francis Jaubert; Shinsaku Imashuku; Lamia Abd Al-Kadar; Katsuyoshi Takata; Tadashi Yoshino
Journal:  Virchows Arch       Date:  2012-12-27       Impact factor: 4.064

Review 10.  Secukinumab: A New Treatment Option for Psoriatic Arthritis.

Authors:  Philip Mease; Iain B McInnes
Journal:  Rheumatol Ther       Date:  2016-04-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.